Skip to main content
Mithra Pharmaceuticals S.A. logo

Mithra Pharmaceuticals S.A. — Investor Relations & Filings

Ticker · MITRA ISIN · BE0974283153 LEI · 5493002FDD273HTEKK14 BR Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-06-11 M&A Activity
Country BE Belgium
Listing BR MITRA

About Mithra Pharmaceuticals S.A.

https://www.mithra.com/

Mithra Pharmaceuticals S.A. is a biotech company dedicated to women's health. The company focuses on the development, manufacturing, and commercialization of differentiated drugs and complex therapeutic solutions. Its core areas of expertise include contraception, fertility, and menopause. Mithra aims to transform the women's health sector by providing innovative choices to support and improve the overall quality of life for women.

Recent filings

Filing Released Lang Actions
2024-06-11_Mithra_Press-Release_Mithra sells to GR_EN-FS (003) (002)-PDF.pdf
M&A Activity Classification · 99% confidence The document announces a significant corporate transaction: the sale of subsidiaries (Neuralis SA, Estetra SRL) and specific assets by Mithra Pharmaceuticals SA to Gedeon Richter for EUR 175 million. This involves the transfer of intellectual property, marketed products (ESTELLE®), and pipeline assets (DONESTA®). This type of major corporate restructuring, asset sale, or merger/acquisition activity falls under the scope of M&A Activity (TAR). It is not a standard periodic financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a direct announcement of a takeover/sale proposal, TAR is the most appropriate classification.
2024-06-11 English
2024-06-11_Mithra_Press-Release_Mithra sells to GR_FR-FS-PDF.pdf
M&A Activity Classification · 99% confidence The document is a press release dated June 11, 2024, announcing a significant corporate transaction: Mithra Pharmaceuticals selling its subsidiaries (Neuralis SA, Estetra SRL) and specific assets to Gedeon Richter for 175 million euros. This announcement details the sale of business lines, intellectual property, and the impact on employees. This type of material, detailing a major corporate event like a divestiture or acquisition, is typically classified as a Regulatory Filing (RNS) if it's a general market announcement that doesn't fit a more specific category like Capital/Financing Update (CAP) or Legal Proceedings (LTR). Since it is a broad announcement of a transaction that affects the company's structure and assets, and it is not a formal financial report (like 10-K or IR), nor a specific management/board change, the most appropriate general regulatory announcement category is RNS. It is not a formal M&A filing (TAR) but rather the announcement of the completion of the transaction.
2024-06-11 French
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_EN.pdf
Legal Proceedings Report Classification · 99% confidence The document announces that Mithra Pharmaceuticals SA has entered bankruptcy proceedings ('opened bankruptcy proceedings against Mithra Pharmaceuticals SA'). It also discusses ongoing negotiations for the sale of assets (Neuralis and Estetra) and the status of related entities under judicial reorganization. This type of announcement, detailing significant corporate restructuring, financial distress, and major legal/financial events outside of standard periodic reporting (like 10-K or IR), most closely aligns with a general regulatory announcement or a significant corporate event disclosure. Since it is not a standard financial report (10-K, IR), an earnings release (ER), or a specific transaction like M&A (TAR), it falls best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard corporate disclosure, or potentially 'Capital/Financing Update' (CAP) due to the bankruptcy and asset sale context. Given the gravity and nature of bankruptcy proceedings being announced, RNS serves as the most appropriate catch-all for major, non-scheduled corporate news that impacts the company's structure and solvency, especially when it doesn't fit the specific M&A or Capital categories perfectly. The document is a direct announcement, not a report itself, satisfying the 'MENU VS MEAL' rule against classifying it as a full report.
2024-06-10 English
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_FR.pdf
Legal Proceedings Report Classification · 99% confidence The document is a press release dated June 10, 2024, announcing that Mithra Pharmaceuticals SA has been declared bankrupt by the Liège Commercial Court. It details the immediate consequences (bankruptcy of the parent company) and ongoing negotiations for asset sales (Neuralis SA and Estetra SRL to Gedeon Richter). This type of announcement, detailing significant corporate events, financial distress, and subsequent strategic actions (like asset sales following bankruptcy), is typically classified as a general corporate announcement or regulatory filing. Since it is not a formal periodic report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific financing/share action (CAP, SHA), the most appropriate general category for significant, non-standard corporate news that impacts operations and structure is 'Regulatory Filings' (RNS), as it serves as a broad catch-all for important corporate disclosures that don't fit elsewhere, especially when related to legal/financial distress proceedings.
2024-06-10 French
2024-0~1.PDF
Legal Proceedings Report Classification · 99% confidence The document is a press release dated June 4, 2024, announcing that Mithra has applied to the Liege Company Courts for an extension of court protection measures related to its CDMO and Novalon SA assets to advance a monetization process. This type of announcement, detailing legal/restructuring proceedings, debt management, and corporate actions outside of standard periodic financial reporting (10-K, IR, ER), fits best under the category of general corporate or regulatory updates. Since it specifically discusses legal proceedings (court protection, judicial reorganization) and corporate restructuring efforts, it aligns closely with 'Legal Proceedings Report' (LTR) or potentially 'Capital/Financing Update' (CAP) due to the monetization context. However, the core subject is the extension of court protection measures and judicial reorganization, which strongly suggests a legal/regulatory matter impacting the company's structure. Given the options, 'LTR' (Legal Proceedings Report) is the most appropriate fit for updates on significant lawsuits or regulatory/judicial actions affecting the company's operations, even if it's self-initiated reorganization under court supervision. It is not a standard ER, IR, or 10-K. It is not a proxy statement (DEF 14A/PSI) or a management change (MANG). It is a specific update on a legal/judicial process.
2024-06-04 English
2024-0~2.PDF
Legal Proceedings Report Classification · 99% confidence The document is a press release dated June 4, 2024, detailing Mithra's request to extend judicial protection measures for its CDMO and Novalon SA assets until June 30, 2024, to facilitate the monetization process. This type of announcement, which communicates ongoing legal/restructuring proceedings and financial strategy updates via a press release format, fits best under the general category of corporate news or regulatory updates that aren't specifically an earnings release (ER), capital change (CAP), or director dealing (DIRS). It is not a full Annual Report (10-K) or Interim Report (IR). It is not a Call Transcript (CT) or Investor Presentation (IP). Since it is a formal announcement regarding the status of restructuring/asset sales under judicial protection, it is a significant corporate event announcement. Given the options, it most closely resembles a general regulatory announcement or a specific update that doesn't fit the other narrow categories. However, since it details ongoing legal/restructuring proceedings and financial strategy updates, and is not a standard financial report, it is best classified as a Regulatory Filing (RNS) as a broad category for significant, non-standard corporate news releases, or potentially a Legal Proceedings Report (LTR) due to the focus on judicial protection, but RNS is a safer general catch-all for press releases detailing operational/legal status updates not covered elsewhere. Considering the content focuses heavily on judicial reorganization and debt restructuring, LTR (Legal Proceedings Report) is a strong candidate. However, LTR is defined as 'Updates on significant lawsuits, regulatory actions, or legal matters'. This is an update on a judicial reorganization process, which is a legal matter. Since the core of the announcement is the extension of judicial protection ('mesures de protection judiciaire'), LTR is more specific than RNS. Revisiting the definitions: LTR is for 'Legal Proceedings Report'. This is an update on a judicial reorganization process, which is a legal matter. I will classify it as LTR.
2024-06-04 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.